Summary
Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m–2, vinblastine 6 mg m–2 and cisplatin 50 mg m–2 (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage; none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III–IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Burkes, R. L., Ginsberg, R. J., Shepherd, F. A., Blackstein, M. E., Goldberg, M. E., Waters, P. F., Patterson, G. A., Todd, T., Pearson, F. G., Cooper, J. D., Jones, D. & Lockwood, G. (1992). Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 10: 580–586.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O’Reilly, S., Burnell, M., Boxall, F. E., Siddick, Z. H., Judson, I. R., Gore, M. E. & Wiltshaw, E. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756.
Cockcroft, D. W. & Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41.
Doyle, L. A., Ihde, D. C., Carney, D. N., Bunn, P. A., Cohen, M. H., Matthews, M. J., Puffenbarger, R., Cordes, R. S. & Minna, J. D. (1984). Combination chemotherapy with doxorubicin and mitomycin C in non-small-cell bronchogenic carcinoma. Severe pulmonary toxicity from q3 weekly mitomycin C. Am J Clin Oncol 7: 719–724.
Ellis, P. A., Smith, I. E., Hardy, J. R., Nicolson, M. C., Talbot, D. C., Ashley, S. E. & Priest, K. (1995). Symptom relief with MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71: 366–370.
Faber, L. P., Kittle, C. F., Warren, W. H., Bonomi, P. D., Taylor, SGIV, Reddy, S. & Lee, M. S. (1989). Preoperative chemotherapy and radiation for stage III non-small cell lung cancer. Ann Thorac Surg 47: 669–677.
Hayward, J. L., Carbone, P. P., Heuson, J-C, Kumaoka, S., Segaloff, A. & Rubens, R. D. (1977). Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298.
Holmes, E. C. & Gail, M. (1986). Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. J Clin Oncol 4: 710–715.
Lad, T., Rubinstein, L. & Sadeghi, A. (1988). The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 6: 9–17.
Linette, D. C., McGee, K. H. & McFarland, J. A. (1992). Mitomycin-induced pulmonary toxicity: case report and review of the literature. Ann Pharmacother 26: 481–484.
Martini, N., Kris, M. G., Flehinger, B. J., Gralla, R. J., Bains, M. S., Burt, M. E., Heelan, R., McCormack, P. M., Pisters, K. M. W., Rigas, J. R., Rausch, V. W. & Ginsberg, R. J. (1993). Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55: 1365–1374.
McCormack, P. M., Bains, M. S., Martini, N., Burt, M. E. & Kaiser, L. R. (1987). Methods of skeletal reconstruction following resection of lung cancer invading the chest wall. Surg Clin North Am 67: 979–986.
Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Mountain, C. F. (1977). Assessment of the role of surgery for control of lung cancer. Ann Thorac Surg 24: 365–373.
Niiranen, A., Niitamo-Korhonen, S., Kouri, M., Assendelft, A., Mattson, K. & Pyrhonen, S. (1992). Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomised study. J Clin Oncol 10: 1927–1932.
Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899–909.
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., Canela, M., Ariza, A., Skacel, Z., Morera-Prat, J. & Abad, A. (1994). A randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153–158.
Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B. Jr, Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., Atkinson, E. N. & Hong, W. K. (1994). A randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86: 673–680.
Skarin, A., Jochelson, M., Sheldon, T., Malcolm, A., Oliynyk, P., Overholt, R., Hunt, M. & Frei, E. (1989). Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long term follow up in 41 patients. J Surg Oncol 40: 266–274.
Slevin, M. L., Stubbs, L., Plant, H. J., Wilson, P., Gregory, W. M., Armes, P. J. & Downer, S. M. (1990). Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. Br Med J 300: 1458–1460.
Strauss, G. M., Herndon, J. E., Sherman, D. D., Mathisen, D. J., Carey, R. W., Choi, N. C., Rege, V. B., Modeas, C. & Green, M. R. (1992). Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10: 1237–1244.
Weiden, P. L. & Piantadosi, S. (1991). Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 83: 266–273.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boer, R., Smith, I., Pastorino, U. et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer 79, 1514–1518 (1999). https://doi.org/10.1038/sj.bjc.6690241
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690241
Keywords
This article is cited by
-
Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer
Pathology & Oncology Research (2015)
-
Clinical study of interventional preoperative bronchial artery infusion chemotherapy combined with surgical resection for advanced non-small cell lung cancer
The Chinese-German Journal of Clinical Oncology (2007)
-
Preoperative chemotherapy for cStage III-pN0 patients with non-small cell lung cancer
The Japanese Journal of Thoracic and Cardiovascular Surgery (2006)